Search Results - "Babyshkina, N"

Integration of phosphoinositide 3-kinase (PI3K) and transforming growth factor β1 (TGF-β1) signaling cascades: role in the therapeutic inefficiency of tamoxifen by Babyshkina, N. N., Uzyanbaev,  I.  A., Dronova,  T.  A., Cherdyntseva, N. V.

“…Growth factors signaling cascades and their interaction with the central regulatory targets of tumor cells and estrogens are considered as the main mechanisms…”
Get full text

Multimodal therapy for metastatic colorectal cancer: a case of complete clinical and radiological response of liver metastases by Dobrodeev, A. Yu, Kostromitsky, D. N., Tarasova, A. S., Afanasyev, S. G., Babyshkina, N. N., Ponomaryeva, A. A., Larionova, I. V., Dronova, T. A., Azovsky, D. I.

“…Background. Colorectal cancer is one of the most common cancers and the second leading cause of cancer-related deaths worldwide. Population-based studies have…”
Get full text

Differentiated approach to adjuvant neutron therapy in patients with locally advanced breast cancer, taking into account signifcant prognostic factors by Velikaya, V. V., Startseva, Zh. A., Babyshkina, N. N., Goldberg, V. E., Popova, N. O.

“…The purpose of the study was to assess the risk of developing local recurrence in patients with locally advanced breast cancer, taking into account unfavorable…”
Get full text

Variability in surgical treatment of metastatic colorectal cancer (literature review) by Dobrodeev, A. Yu, Kostromitsky, D. N., Afanasyev, S. G., Tarasova, A. S., Babyshkina, N. N., Ponomareva, A. A.

“…Background . Colorectal cancer (CRC) is one of the most common cancers and one of the most leading causes of cancer-related deaths worldwide. Approximately 35…”
Get full text

Exome Sequencing: the Search for Mutations Associated with Hereditary Breast and Ovarian Cancers in the Tuvan Ethnic Group (A Pilot Study) by Gervas, P., Molokov, A., Zarubin, A., Shivit-Ool, A. A., Babyshkina, N., Shefer, N., Topolnitsky, E., Pisareva, L., Choinzonov, E., Cherdyntseva, N.

“…Whole exome sequencing of peripheral blood samples from Tuvan females diagnosed with breast and ovarian cancers (BC/OC) was performed to search for new genes…”
Get full text

Nivolumab monotherapy in metastatic colorectal cancer: current approaches to response evaluation by Babyshkina, N. N., Dronova, T. A., Gervas, P. A., Popova, N. O., Dobrodeev, A. Yu, Kostromitsky, D. N., Afanasyev, S. G., Goldberg, V. E., Cherdyntseva, N. V.

“…Aim of the study: a systematic analysis of the modern literature data on the nivolumab monotherapy efficacy in patients with metastatic colorectal cancer…”
Get full text

ROR1 and BMI-1 proteins as potential predictors of the effectiveness of hormone therapy in luminal breast cancer by Tarakanova, V. O., Krakhmal, N. V., Patalyak, S. V., Tarasov, M. N., Babyshkina, N. N., Vtorushin, S. V.

“…The purpose of the study was to generalize information regarding the molecular and biological mechanisms involved in the resistance to endocrine therapy with…”
Get full text

Short-term outcomes of neoadjuvant chemotherapy in colorectal cancer patients with isolated liver metastasis by Dobrodeev, A. Yu, Kostromitsky, D. N., Tarasova, A. S., Afanasyev, S. G., Babyshkina, N. N., Ponomaryeva, A. A., Ermolenko, R. V., Frolova, I. G., Cheremisina, O. V.

“…The purpose of the study was to assess the short-term effcacy and tolerability of neoadjuvant chemotherapy (NAC) in colorectal cancer (CRC) patients with…”
Get full text

Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Contributes to Tamoxifen Resistance in Estrogen-Positive Breast Cancer Patients by Dronova, T. A., Babyshkina, N. N., Zavyalova, M. V., Slonimskaya, E. M., Cherdyntseva, N. V.

“…Crosstalk between the estrogen receptors and the receptor tyrosine kinases, including vascular endothelial growth factor receptor type II (VEGFR2), is a key…”
Get full text

New mutation of the TP53 gene associated with the hereditary breast cancer in a young Tuvinian woman by Gervas, P. A., Molokov, A. Yu, Zarubin, A. A., Ponomareva, A. A., Babyshkina, N. N., Belyavskaya, V. A., Pisareva, L. F., Choynzonov, E. L., Cherdyntseva, N. V.

“…Background. The identification of the ethnospecific mutations associated with hereditary breast cancer remains challenging. Next generation sequencing (Ngs)…”
Get full text

Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Contributes to Tamoxifen Resistance in Estrogen-Positive Breast Cancer Patients by Dronova, T A, Babyshkina, N N, Zavyalova, M V, Slonimskaya, E M, Cherdyntseva, N V

“…Crosstalk between the estrogen receptors and the receptor tyrosine kinases, including vascular endothelial growth factor receptor type II (VEGFR2), is a key…”
Get more information

The role of epidermal growth factor receptor (EGFR) in the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer patients by Babyshkina, N. N., Dronova, T. A., Zambalova, E. A., Zavyalova, M. V., Slonimskaya, E. M., Cherdyntseva, N. V.

“…Background. Identification of predictive molecular markers of triple-negative breast cancer (TNBC) will enable the evaluation of the efficacy of neoadjuvant…”
Get full text

ROLE OF CYCLIN D1 IN THE MECHANISMS OF TAMOXIFEN RESISTANCE by Erdyneeva, D. B., Babyshkina, N. N., Dronova, T. A., Vtorushin, S. V., Slonimskaya, E. M., Stegniy, V. N., Cherdyntseva, N. V.

“…Hormone-receptor positive breast cancer is the most common molecular subtype and represents 60–75 % of all breast cancers (BC). The presence of specific…”
Get full text

Relation of EGFR/PI3K/AKT signaling components with tamoxifen efficacy in patients with estrogen-dependent breast cancer by Dronova, T. A., Babyshkina, N. N., Zavyalova, M. V., Patalyak, S. V., Slonimskaya, E. M., Cherdyntseva, N. V., Kzhyshkowska, J. G.

“…Background. It is generally accepted that crosstalk between the growth factor receptor and ER pathways implicated in tamoxifen resistance. The aim of the study…”
Get full text

P6 by Babyshkina, N, Vtorushin, S, Patalyak, S, Dronova, T, Slonimskaya, E, N.Cherdyntseva

“…Background Tamoxifen, a selective estrogen receptor modulator, remains a standard of endocrine therapy for estrogen receptor alpha (ER α ) positive breast…”
Get full text

Mesenchymal Subtype of Triple-Negative Breast Cancer: A Review of Specific Features by Krakhmal, Nadezhda, Babyshkina, Natalia, Vtorushin, Sergey

“…Triple-negative breast cancer (TNBC) is characterized by high invasiveness, high metastatic potential, proneness to relapse, and poor prognosis. Currently,…”
Get full text

Predictive Significance of Vascular Endothelial Growth Factor receptor VEGF-2 in triple-negative breast cancer patients by Babyshkina, N. N., Zavyalova, M. V., Bragina, O. D., Dronova, T. A., Slonimskaya, E. M., Cherdyntseva, N. V.

“…The identification of informative biomarkers that are able to predict prognosis and treatment response may be particularly important in triple negative breast…”
Get full text

Crosstalk between the FGFR2 and TP53 genes in breast cancer: data from an association study and epistatic interaction analysis by Cherdyntseva, Nadezhda V, Denisov, Evgeny V, Litviakov, Nicolay V, Maksimov, Vladimir N, Malinovskaya, Elena A, Babyshkina, Natalia N, Slonimskaya, Elena M, Voevoda, Mikhail I, Choinzonov, Evgeny L

“…To evaluate the potential for gene-gene interaction effects in sporadic breast cancer (BC) risk, we studied combinations of the fibroblast growth factor…”
Get more information

ROLE OF TRANSFORMING GROWTH FACTOR RECEPTOR B I TYPE (TGF-BRI) IN THE PROGRESSION OF THE LUMINAL BREAST CANCER SUBTYPE by Babyshkina, N. N., Vtorushin, S. V., Dronova, T. A., Krakhmal, N. V., Zavyalova, M. V., Tsyganov, M. M., Patalyak, S. V., Slonimskaya, E. M., Cherdyntseva, N. V.

“…Introduction. The crosstalk between the estrogen and growth factor receptors signaling may play an important role in the resistance to endocrine therapy. The…”
Get full text

P190 Molecular breast cancer subtypes: relationship with clinicopathological characteristics, efficacy of neoadjuvant chemotherapy and survival by Babyshkina, N, Malinovskaya, E, Zavyalova, M, Cherdyntseva, N, Slonimskaya, E

Get full text